Scientists at Life Biosciences are preparing to begin testing partial reprogramming in people. It will mark the first time ...

One of the most studied lifespan-extending drugs in animals has just failed its test on humans in a 13-week clinical trial co ...

A burgeoning field is launching its first clinical trial to find out whether dialing back cell development can safely refresh ...

India, April 13 -- Life Biosciences, a clinical-stage biotechnology company focused on reversing diseases of aging, has ...

The field of partial reprogramming is transitioning from successful mouse studies to its first human clinical trials. At the heart of this experiment lies the discovery of Yamanaka ...

Funding to support the Phase 1 clinical trial of ER-100 in optic neuropathies and further investigation of new candidates from the company’s Partial Epigenetic Reprogramming platform ...

Scientists at the Salk Institute for Biological Studies and Sanford Burnham Prebys explore genetic factors in separate papers ...

Some jellyfish possess the extraordinary ability to revert their cells back to an earlier developmental stage, effectively ...

The company described the round as fully subscribed and said the cash should keep operations running into the second half of ...

Rather than scrambling to repair itself only after injury occurs, a Korean research team has demonstrated that ...